CORT

Corcept Therapeutics Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.

Did you know?

Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.

Current Price

$51.42

+10.53%

GoodMoat Value

$16.61

67.7% overvalued

Profile

Valuation (TTM)

Market Cap$5.47B

P/E117.20

EV—

P/B8.44

Shares Out106.37M

P/Sales7.11

Revenue$769.10M

EV/EBITDA—

Corcept Therapeutics Inc (CORT) Valuation

CORT Fair Value Estimate

$16.6167.7% overvalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

CORT Valuation Metrics

FCF$141.78M

FCF Growth Rate0.82%

EPS Growth (CAGR)0.69%

WACC10.00%

Fair Value Models

Graham Number, PEG-based, and Earnings-based models

View Fair Value →

CORT Valuation & Fair Value Analysis

Corcept Therapeutics Inc (CORT) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Corcept Therapeutics Inc is $16.61. The current stock price is $51.42, suggesting the stock is 209.6% overvalued.

The price-to-earnings (P/E) ratio is 117.20. Price-to-book ratio is 8.44. Price-to-sales ratio is 7.11. PEG ratio is -0.45.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Corcept Therapeutics Inc's intrinsic value.